18:29 , May 15, 2018 |  BC Innovations  |  Distillery Techniques

Drug delivery

TECHNOLOGY: Targeting domains Tannic acid conjugates of therapeutic proteins or viral particles could be used for cardiac-specific delivery of therapies for myocardial infarction (MI) and other heart diseases. The method involves conjugating therapeutic proteins or viral...
21:16 , May 17, 2017 |  BC Week In Review  |  Clinical News

Proteon's vonapanitase receives breakthrough therapy designation

Proteon Therapeutics Inc. (NASDAQ:PRTO) said FDA granted breakthrough therapy designation to vonapanitase to increase arteriovenous fistula (AVF) secondary patency in patients on or expected to start hemodialysis. The recombinant human elastase is in the Phase III...
20:36 , May 12, 2017 |  BC Week In Review  |  Clinical News

Proteon ups Phase III PATENCY-2 enrollment

Proteon Therapeutics Inc. (NASDAQ:PRTO) will for the second time increase enrollment in the ongoing Phase III PATENCY-2 trial of vonapanitase to treat chronic kidney disease (CKD) to correct a calculation error in the trial’s statistical...
16:25 , Mar 17, 2017 |  BC Week In Review  |  Clinical News

Vonapanitase: Ph III PATENCY-2 amended

Proteon amended the double-blind, placebo-controlled, North American Phase III PATENCY-2 trial of vonapanitase given immediately after radiocephalic AVF to increase enrollment to 500 patients from 300 and to establish secondary patency and fistula use for...
20:24 , Dec 16, 2016 |  BC Week In Review  |  Clinical News

Vonapanitase: Ph III PATENCY-1 data

Top-line data from the double-blind, U.S. Phase III PATENCY-1 trial in 313 CKD patients receiving or expecting hemodialysis who underwent surgical creation of a radiocephalic AVF showed that a single dose of 30 µg vonapanitase...
00:02 , Dec 14, 2016 |  BC Extra  |  Clinical News

Proteon crumbles after Phase III patency miss

Proteon Therapeutics Inc. (NASDAQ:PRTO) plummeted $7.40 (75%) to $2.50 after it said vonapanitase (formerly PRT-201) missed the primary endpoint in the Phase III PATENCY-1 trial in patients with chronic kidney disease (CKD). Compared to placebo,...
20:29 , Nov 11, 2016 |  BC Week In Review  |  Clinical News

Vonapanitase: Ph I started

Proteon began a double-blind, placebo-controlled, dose-escalation, U.S. Phase I trial to evaluate a single perivascular injection of vonapanitase delivered via micro-infusion catheter in up to 40 patients immediately following angioplasty of a distal popliteal, tibial...
07:00 , Apr 4, 2016 |  BC Week In Review  |  Company News

PhaseBio, Duke University deal

PhaseBio granted the university exclusive rights to conjugate small molecule oncologic ( SMO) drugs to PhaseBio’s Elastin-Like Polypeptide (ELP) technology. The resulting compounds are known as High Transition Temperature ELP-SMO ( HTT ELP-SMO). PhaseBio will...
08:00 , Dec 7, 2015 |  BC Week In Review  |  Clinical News

PE0139: Phase IIa started

PhaseBio began a double-blind, placebo-controlled, U.S. Phase IIa trial to evaluate once-weekly subcutaneous PE0139 for 6 weeks in up to 47 patients. PhaseBio Pharmaceuticals Inc., Malvern, Pa.   Product: PE0139   Business: Endocrine/Metabolic   Molecular target: NA...
07:00 , Apr 2, 2015 |  BC Innovations  |  Targets & Mechanisms

Breathing through bone drugs

Reversing or halting progressive airway damage is still the biggest challenge in COPD, but a study from Japan suggests a subclass of osteoporosis drugs could offer a new way to tackle the disease that takes...